
As COVID-19 approaches its fourth year, Omicron continues to mutate and become more immune evasive. But what does mutation mean, what doesn't it mean and why does immune evasiveness matter? Here are some answers based on what we know at this stage in the pandemic.
from CBC | Health News https://ift.tt/v9MudCG
Aucun commentaire:
Enregistrer un commentaire